This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.
Purpose: To estimate the vitamin D status of participants residing in Malaysia.Methods: PubMed, Scopus, Web of Science, and MyJurnal were searched up to June 2022 without language restrictions. Studies that reported the 25-hydroxyvitamin D [25(OH)D] concentrations and defined their cut-off for deficiency or insufficiency from healthy participants residing in Malaysia were included. The random effects model was used to pool vitamin D status using established cut-offs of <30, <50, and <75 nmol/L according to age group.Results: From 299 studies screened, 32 studies were included in the meta-analysis. The pooled proportion for <30 nmol/L was 21% (95% CI 9–36, n = 2,438 from 10 studies), while the pooled proportion <50 nmol/L was 64% (95% CI 56–72, n = 13,977 from 30 studies), and <75 nmol/L was 85% (95% CI 61–100, n = 1,376 from five studies). Heterogeneity was high (I2 ranged from 98–99%). Higher proportions of vitamin D insufficiency (defined as <50 nmol/L) were found in participants living in the urban areas (compared to rural areas), in females (compared to males), and in Malays and Malaysian Indians (compared to Malaysian Chinese) ethnicities.Conclusion: More than half of Malaysians have insufficient vitamin D levels, despite being a country that is close to the equator. We strongly urge prompt public health measures to improve the vitamin D status in Malaysia.Systematic review registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021260259].
The aim of this study was to compare the predictive performance of different warfarin dosing methods. Data from 46 patients who were initiating warfarin therapy were available for analysis. Nine recently published dosing tools including 8 dose prediction algorithms and a Bayesian forecasting method were compared with each other in terms of their ability to predict the actual maintenance dose. The dosing tools included 4 algorithms that were based on patient characteristics (2 clinical and 2 genotype-driven algorithms), 4 algorithms based on international normalized ratio (INR) response feedback and patient characteristics (2 clinical and 2 genotype-driven algorithms), and a Bayesian forecasting method. Comparisons were conducted using measures of bias (mean prediction error) and imprecision [root mean square error (RMSE)]. The 2 genotype-driven INR feedback algorithms by Horne et al and Lenzini et al produced more precise maintenance dose predictions (RMSE, 1.16 and 1.19 mg/d, respectively; P < 0.05) than the genotype-driven algorithms by Gage et al and Klein et al and the Bayesian method (RMSE, 1.60, 1.62, and 1.81 mg/d respectively). The dose predictions from clinical and genotype-driven algorithms by Gage et al, Klein et al, and Horne et al were all negatively biased. Only the INR feedback algorithms (clinical and genotype) by Lenzini et al produced unbiased dose predictions. The Bayesian method produced unbiased dose predictions overall (mean prediction error, +0.37 mg/d; 95% confidence interval, 0.89 to -0.15) but overpredicted doses in patients requiring >8 mg/d. Overall, warfarin dosing methods that included some measure of INR response (INR feedback algorithms and Bayesian methods) produced unbiased and more precise dose predictions. The Bayesian forecasting method produced positively biased dose predictions in patients who required doses >8 mg/d. Further research to assess differences in clinical endpoints when warfarin doses are predicted using Bayesian or INR-driven algorithms is warranted.
9 January 2025 in Journal of Thrombosis and Haemostasis